Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.

Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, Wu TC, Trimble CL, Hung CF.

Clin Cancer Res. 2014 Nov 1;20(21):5456-67. doi: 10.1158/1078-0432.CCR-14-0344. Epub 2014 Jun 3.

2.

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.

Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, Wu TC.

Clin Cancer Res. 2016 Feb 1;22(3):657-69. doi: 10.1158/1078-0432.CCR-15-0234. Epub 2015 Sep 29.

3.

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination.

Chuang CM, Monie A, Hung CF, Wu TC.

J Biomed Sci. 2010 Apr 28;17:32. doi: 10.1186/1423-0127-17-32.

4.

Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.

Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.

Mucosal Immunol. 2013 Mar;6(2):393-404. doi: 10.1038/mi.2012.83. Epub 2012 Sep 12.

5.

Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.

Lee SY, Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC.

J Mol Med (Berl). 2013 Oct;91(10):1221-31. doi: 10.1007/s00109-013-1054-9. Epub 2013 May 29.

6.

Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.

Sun Y, Peng S, Qiu J, Miao J, Yang B, Jeang J, Hung CF, Wu TC.

Gene Ther. 2015 Jul;22(7):528-35. doi: 10.1038/gt.2015.17. Epub 2015 Mar 19.

7.

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.

Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI.

Vaccine. 2009 Sep 4;27(40):5450-9. doi: 10.1016/j.vaccine.2009.07.005. Epub 2009 Jul 19.

8.

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.

Seo SH, Jin HT, Park SH, Youn JI, Sung YC.

Vaccine. 2009 Sep 25;27(42):5906-12. doi: 10.1016/j.vaccine.2009.07.033. Epub 2009 Aug 3.

PMID:
19651174
9.

Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.

Li YL, Qiu XH, Shen C, Liu JN, Zhang J.

Oncol Rep. 2010 Nov;24(5):1323-9.

PMID:
20878127
10.

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC.

J Virol. 2004 Aug;78(16):8468-76.

11.

Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.

Lasaro MO, Diniz MO, Reyes-Sandoval A, Ertl HC, Ferreira LC.

Microbes Infect. 2005 Dec;7(15):1541-50. Epub 2005 Sep 9.

PMID:
16213178
12.

Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.

Diniz MO, Lasaro MO, Ertl HC, Ferreira LC.

Clin Vaccine Immunol. 2010 Oct;17(10):1576-83. doi: 10.1128/CVI.00264-10. Epub 2010 Aug 25.

13.

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.

Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, Hung CF, Wu TC.

Cancer Immunol Immunother. 2013 Jul;62(7):1175-85. doi: 10.1007/s00262-013-1421-y. Epub 2013 Apr 25.

14.

Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects.

Tseng CW, Monie A, Trimble C, Alvarez RD, Huh WK, Buchsbaum DJ, Straughn JM Jr, Wang MC, Yagita H, Hung CF, Wu TC.

Vaccine. 2008 Aug 12;26(34):4314-9. doi: 10.1016/j.vaccine.2008.06.049. Epub 2008 Jul 1.

15.

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Manuri PR, Nehete B, Nehete PN, Reisenauer R, Wardell S, Courtney AN, Gambhira R, Lomada D, Chopra AK, Sastry KJ.

Vaccine. 2007 Apr 30;25(17):3302-10. Epub 2007 Jan 24.

16.

Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.

Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, Chuang CM, Lin CT, Tsai YC, He L, Monie A, Wu TC.

Clin Cancer Res. 2008 May 15;14(10):3185-92. doi: 10.1158/1078-0432.CCR-08-0037.

17.
18.

Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects.

Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, Hung CF, Wu TC.

Gene Ther. 2008 Aug;15(16):1156-66. doi: 10.1038/gt.2008.53. Epub 2008 Apr 10.

19.

Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.

Shin TH, Pankhong P, Yan J, Khan AS, Sardesai NY, Weiner DB.

Hum Vaccin Immunother. 2012 Apr;8(4):470-8. doi: 10.4161/hv.19180. Epub 2012 Feb 16.

20.

Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.

Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC.

Gene Ther. 2010 Apr;17(4):531-40. doi: 10.1038/gt.2009.152. Epub 2009 Nov 26.

Supplemental Content

Support Center